During a session at this week’s Consumer Electronics Show, Andrea Wainer, EVP of Rapid Molecular Diagnostics at Abbott, shares how the company scaled up to supply the global market with more than 300 million COVID-19 tests in 2020 and the path forward.
A review of new, successful treatment options for the novel coronavirus.
Fueled by an urgent need for diagnostic testing to respond to COVID-19, the in-vitro diagnostics market is experiencing explosive growth across Asia and around the globe.
During the current operating environment there has been an increased need for healthcare training using patient simulators for students and practicing healthcare professionals.
In general, the Asian markets have controlled the COVID-19 virus successfully outside of China, but its effect has still led to new developments and trends.
With everything to gain, telehealth may lead to a new standard in health/wellness treatment while at the same time unifying the entire healthcare ecosystem.
Having the ability to assess vital signs in real time could be the future of monitoring the health of travelers to help prevent outbreaks.
One goal is to develop a fast, non-invasive way to evaluate skin rashes, such as ‘COVID toes’, for ischemia.
Medtech companies will need to collaborate more closely with other parties in healthcare, as the aftermath of the coronavirus pandemic will have a comprehensive reach throughout the entire ecosystem. MTI speaks with Johnson & Johnson VP Raymond Fryrear, M.D. on the topic.
Illumina’s COVIDSeq Test enables qualitative detection of SARS-CoV-2 RNA from respiratory specimens.